|

CODY SHANDRAW: The MOST Important Factor Before Investing In Psychedelic Companies



In this interview, David Flores sits down with Cody Shandraw, the managing partner at Ambria Capital.

Ambria Capital is an investment firm which focuses on investing in psychedelic therapies and technologies. In this episode they discuss the psychedelic space in general and Ambria’s approach to investing.

Cody acknowledges that many companies in the space will fail, but the ones who succeed will transform the mental health landscape. That is a risk that Ambria Capital is willing to take to be involved in the psychedelic transformation that is unfolding.
Psychedelics are changing people’s lives, and Ambria Capital wants to make sure that these companies are financed to do so…And maybe make some money on the successful companies.

Cody acknowledges that his family has had lots of addiction issues, so this issue is personal for him. If psychedelics can help addiction, it would be a game changer.

Cody discusses how the most important thing for deciding which company to invest in, is the management teams, regardless of whether they work with psilocybin, lsd, mescaline or other compounds.
Cody really likes PsyHealth.

We all know someone who has been affected by addiction, depression, anxiety, or other mental health issues. We all want to find solutions to help these people.

#AmbriaCapital #Psychedelics #PsychedelicTherapy

source

Similar Posts

  • Can Ketamine Treat Depression? Meet Delic, the LARGEST Ketamine Clinic Company

    In today’s episode, I talk with Matt Stang, CEO of Delic Corp. Delic (OTCMKTS: DELCF) is a psychedelic medicines company aiming to put a dent in the mental health crisis.
    They are doing this in three ways.

    First, through their ketamine clinics. Delic runs the largest ketamine network in the world, with dozens of clinics across North America. At the moment, these clinics are only providing ketamine therapy for disorders like depression, but in the future, once they become legal, Delic also plans on offering other psychedelic therapies such as psilocybin and MDMA therapy.

    Second, through education. Delic runs multiple media platforms, such as RealitySandwich.com. These media platforms aim to educate and entertain, leading towards the destigmatization of psychedelics in our culture. As many of the people behind Delic Corp were behind the legendary High Times Magazine, this is an area of expertise for the company. Ultimately, psychedelic compounds will never succeed as medicines if society does not get behind them. Delic also has podcasts, and they host psychedelic medicine events.

    And third, through science. Delic Labs is currently working on creating next generation psychedelics. Delic Labs also works with third parties, completing research, which allows the labs to run on a profit.

    Taken together, Delic is not only a core player in the psychedelics movement, but they are also one of the companies making a solid revenue.

    Enjoy the episode!
    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor
    James’ Twitter: @Psy_Invest
    Maria’s Twitter (Producer & Editor): @Psy_Holy

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Video editing: @themyaholy @Psy_holy

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. Psychedelic Spotlight and The Psychedelic Investor were hired for this video, on December 3rd, 2021, to publicly disseminate information about (DELIC CORP) via digital communications. We have been paid ($2000 CAD).

    #Delic #Psychedelics #Ketamine

  • Welcome to Plant Medicine Week, by Microdose. Join the Psychedelic Revolution

    Buy tickets for Plant Medicine Week in Malta, April 5th-8th by using our promo link: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC

    Get 50% off tickets via the link above or by inputting code PSYC at the checkout over at plantmedicineweek.com/tickets!

    Do you both love learning about psychedelics, and need a vacation in beautiful Malta? Well you are in luck, because Microdose.buzz is hosting a one of a kind event next month.

    Follow us on Twitter:
    @Psy_Invest
    @psy_holy
    @PsycSpotlight

    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    At the event you will be able to learn about the medical benefits, research, and business of psychedelics, as well as marijuana. The all-star studded line-up includes representatives from companies such as atai Life Sciences (ATAI), Awakn Life Sciences (AWKN, AWKNF) and more.

    From panels on psychedelics and sex, to how to make money investing in psychedelics, this event will have it all. Plus…AFTER PARTIES!

    No matter if you want to learn about LSD, MDMA, psilocybin, ketamine or more, this event will have it all. We already know that psychedelics can help with mental health, now hear it first hand from the scientists themselves.

    #Psychedelics #MentalHealth #Microdose

  • Interview with Victoria and Joël, of Tandava Retreats

    Swati sits down with leaders from Kaivalya Kollectiv, “a multifaceted company focusing on psychedelic wellness, education”, and more. She speaks with Victoria Wueshner, a 5-MeO-DMT Facilitator and the Founder of FIVE, and Joël Brierre, CEO of Kaivalya Kollectiv.

  • Is MindMed Expanding to PSILOCYBIN? (BIG MMED / MMEDF Stock NEWS)

    In today’s episode, we will be covering some Massive MindMed news that broke on January 14th that lead me to believe that MindMed might be expanding to psilocybin.
    Mindmed stock, MMED on the Canadian NEO market, and MMEDF on the American OTC market led with a press release entitled “MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience”. MindMed revealed that the company has added a scientist named Robert Barrow as their Chief Development Officer.
    Tucked away in this news release about a hiring decision is a quote which points to a future MindMed project
    And that project will be researching the effects of Psilocybin
    So up until now, MindMed has focused all their phase 2 trials on LSD and 18-MC, which is a derivative of Ibogaine, while leaving treating maladies with psilocybin to other companies like Compass Pathways (NASDAQ:CMPS).
    So, Barrow is bringing with him to MindMed intimate knowledge about the efficacy of psilocybin in treating MDD, as well as dosing data and regime set up.
    MindMed (MMED/MMEDF) has some phase 1 trials looking at the safety of psilocybin in conjunction with the Liechti Lab at the University Hospital Basel
    and is also comparing psilocybin to LSD in a phase 1 trial. MindMed also has a licence to test psilocybin. However, MindMed has yet to start a trial specifically looking at psilocybin as a medicine..

    So does this mean that MindMed’s hiring decision is related to the company’s plans on expanding their clinical trial pipeline to include a psilocybin treatment, sometime in the future? If that speculation turns out to be true, that decision will further expand MindMed’s potential product pipeline as well as the MindMed stock.

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
    https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed #MMED #MMEDF

  • Find Your Inner Healing with Psychedelic Therapy | ATMA CEO Interview

    In today’s episode of PSYCBiz, James, the Psychedelic Investor, sits down with David Harder, Co-CEO of ATMA.

    ATMA is a company that is primarily focused on training therapists on how to conduct psychedelic therapy.

    The company also has plans to launch psilocybin clinical trials, treat depression patients in Canada under the SAP program, and work with Oregon in their legalization of psilocybin therapy.

    This interview took place at the Catalyst Summit, a psychedelic conference that David Harder helped organize. This conference saw big names like Paul Stamets attend.

    In the conversation, David and James get philosophical and discuss the nature of psychedelics and consciousness. Topics such as the right to try are also discussed.

    To learn more about ATMA, visit: https://www.atmajourney.com/
    To learn more about Catalyst, visit: https://catalystpresents.ca/

    #psychedelics #therapy #magicmushrooms